322 related articles for article (PubMed ID: 22440966)
1. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 by fusion inhibitors.
Eggink D; Berkhout B; Sanders RW
Curr Pharm Des; 2010; 16(33):3716-28. PubMed ID: 21128887
[TBL] [Abstract][Full Text] [Related]
3. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
4. Entry inhibitors and their use in the treatment of HIV-1 infection.
Haqqani AA; Tilton JC
Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
[TBL] [Abstract][Full Text] [Related]
5. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
6. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
7. Chemokine receptors as new molecular targets for antiviral therapy.
Santoro F; Vassena L; Lusso P
New Microbiol; 2004 Apr; 27(2 Suppl 1):17-29. PubMed ID: 15646061
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
9. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.
Yi HA; Fochtman BC; Rizzo RC; Jacobs A
Curr HIV Res; 2016; 14(3):283-94. PubMed ID: 26957202
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
12. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
13. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
14. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
Gómara MJ; Haro I
Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
[TBL] [Abstract][Full Text] [Related]
15. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
16. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
18. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
[TBL] [Abstract][Full Text] [Related]
19. Evolved Proteins Inhibit Entry of Enfuvirtide-Resistant HIV-1.
Ikeda T; Tennyson RL; Walker SN; Harris RS; McNaughton BR
ACS Infect Dis; 2019 Apr; 5(4):634-640. PubMed ID: 30811933
[TBL] [Abstract][Full Text] [Related]
20. Reduced Susceptibility to VIRIP-Based HIV-1 Entry Inhibitors Has a High Genetic Barrier and Severe Fitness Costs.
Müller JA; Glöckle A; Gawanbacht A; Geyer M; Münch J; Kirchhoff F
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
